How do CRISPR-based flu assays differ from RT-PCR in clinical workflow requirements?

CRISPR assays run at constant temperature and need no thermocycler, cutting instrument costs by roughly 60% versus RT-PCR setups [21]. Results are typically available in 45 minutes with minimal hands-on steps. Read More

What procurement model offers the best total cost of ownership for mid-size hospital laboratories?

Reagent-rental agreements bundle analyzer placement with per-test consumable pricing, eliminating upfront capital expenditure [14]. This model favors facilities running 20–50 influenza tests daily during peak season. Read More

How does the WHO prequalification process affect market entry timelines for new influenza diagnostics?

WHO prequalification requires 12–18 months of clinical validation data from at least two geographic regions [9]. Manufacturers targeting LMIC procurement channels cannot access PAHO or Global Fund purchasing without this certification. Read More

What impact do flu vaccine mismatch seasons have on diagnostic testing volumes?

Mismatch years increase symptomatic patient presentations by 15–25%, driving proportional rises in diagnostic test orders [16]. Laboratories typically see peak-week volumes spike 30% above matched-season averages. Read More

How are telehealth platforms integrating influenza diagnostic pathways?

Several U.S. telehealth providers now ship OTC flu test kits to patients and initiate antiviral prescriptions based on positive results within a single virtual visit [6]. This test-and-treat model bypasses traditional laboratory workflows entirely. Read More

What cybersecurity considerations apply to connected influenza diagnostic instruments?

Network-connected analyzers transmit patient health information requiring HIPAA-compliant encryption and access controls [3]. FDA's 2024 premarket cybersecurity guidance mandates threat modeling for all Class II connected diagnostic devices. Read More

How does the Influenza Diagnostics Market address co-infection scenarios with RSV and COVID-19?

Multiplex panels detect all three pathogens from a single specimen, reducing swab burden and enabling targeted antiviral therapy within one clinical encounter [10]. Reimbursement parity for triplex panels was established in the U.S. in January 2025. Read More

What is the current size of the influenza diagnostics market?

The influenza diagnostics market reached USD 1.94 billion in 2025 and is projected to reach USD 3.53 billion by 2035. Read More

What is the CAGR of the influenza diagnostics market?

The influenza diagnostics market is projected to grow at a CAGR of 6.15% during the forecast period 2026–2035. Read More

Which region leads the influenza diagnostics market?

North America holds the largest share at 40.0%, while Asia-Pacific is the fastest-growing region at 8.40% CAGR. Read More

What is driving growth in the influenza diagnostics market?

Growth in the influenza diagnostics market is primarily driven by the migration from traditional culture-based methods to molecular diagnostic platforms, rising government surveillance funding, and growing adoption of at-home and point-of-care testing. Read More

Influenza Diagnostics Market (2026 - 2035)

ID: MRFR/MED/2264-CR

153 Pages

Satyendra Maurya

Last Updated: June 27, 2026

Influenza Diagnostics Market Research Report: Size, Share, Trend Analysis By Types (PCR Tests, Antigen Tests, Serology Tests, Viral Culture, Rapid Diagnostic Tests), By Product (Reagents, Kits, Instruments, Consumables), By End Users (Hospitals, Clinics, Laboratories, Home Care), By Technique (Molecular Diagnostics, Immunodiagnostics, Cell Culture) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Influenza Diagnostics Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)6.15%

2025 Market SizeUSD 1.94 Billion

2035 Market SizeUSD 3.53 Billion

Key Players

Roche Diagnostics

Abbott Laboratories

QuidelOrtho Corporation

Hologic Inc.

bioMérieux SA

Cepheid

Trends

Molecular Platform Migration
Government Surveillance Funding
At-Home and POC Test Adoption

Opportunities

Multiplex Respiratory Panel Expansion
Emerging Market Laboratory Buildout
Data Monetization through Syndromic Surveillance

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Molecular Platform Migration | |
  2. 3.1.2 Government Surveillance Funding | |
  3. 3.1.3 At-Home and POC Test Adoption | |
  4. 3.1.4 AI-Enabled Laboratory Workflow Optimization | |
  5. 3.1.5 Multiplex Respiratory Panel Expansion | |
  6. 3.1.6 Seasonal Flu Vaccine Mismatch Episodes | |
  7. 3.1.7 Emerging Market Lab Infrastructure Buildout |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Reimbursement Compression for Rapid Tests | |
  2. 3.2.2 Seasonal Demand Volatility | |
  3. 3.2.3 Regulatory Approval Timelines for Novel Assays | |
  4. 3.2.4 Limited Cold-Chain Infrastructure in LMICs | |
  5. 3.2.5 Competitive Displacement by Multiplex Panels |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Multiplex Respiratory Panel Expansion | |
  2. 3.3.2 Emerging Market Laboratory Buildout | |
  3. 3.3.3 Data Monetization through Syndromic Surveillance | |
  4. 3.3.4 CRISPR-Based Assay Commercialization | |
  5. 3.3.5 Veterinary and Agricultural Influenza Screening |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Influenza Diagnostics Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Test Type | |
  1. 5.1.1 Traditional Diagnostic Tests | | |
    1. 5.1.1.1 Rapid Influenza Diagnostic Tests | | |
    2. 5.1.1.2 Viral Culture | | |
    3. 5.1.1.3 Other Traditional Tests | |
  2. 5.1.2 Molecular Diagnostic Tests | | |
    1. 5.1.2.1 RT-PCR | | |
    2. 5.1.2.2 LAMP | | |
    3. 5.1.2.3 Other Molecular Tests (incl. CRISPR) |
2. 5.2 By End User | |
  1. 5.2.1 Hospitals and Clinical Laboratories | |
  2. 5.2.2 Independent Diagnostic Laboratories | |
  3. 5.2.3 Point-of-Care Settings | |
  4. 5.2.4 Other End Users
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Roche Diagnostics | |
  2. 7.3.2 Abbott Laboratories | |
  3. 7.3.3 QuidelOrtho Corporation | |
  4. 7.3.4 Hologic Inc. | |
  5. 7.3.5 bioMérieux SA | |
  6. 7.3.6 Becton, Dickinson and Company | |
  7. 7.3.7 Cepheid (Danaher) | |
  8. 7.3.8 Thermo Fisher Scientific | |
  9. 7.3.9 Meridian Bioscience | |
  10. 7.3.10 Siemens Healthineers
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Integrated Diagnostic Workflows |
2. 8.2 Platform Convergence and Multiplex Economics |
3. 8.3 Decentralized and At-Home Testing Expansion |
4. 8.4 One Health Surveillance Integration
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Influenza Diagnostics Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Influenza Diagnostics Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Influenza Diagnostics Market – Driver Impact Analysis |
TABLE 4 Global Influenza Diagnostics Market – Restraint Impact Analysis |
TABLE 5 Global Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 6 Global Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 7 Global Influenza Diagnostics Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 8 North America Influenza Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 Europe Influenza Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Asia-Pacific Influenza Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 South America Influenza Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 Middle East & Africa Influenza Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 Competitive Benchmarking Matrix – Global Influenza Diagnostics Market, 2025 |
TABLE 14 Company Profiles – Key Players, Global Influenza Diagnostics Market |
TABLE 15 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 16 Report Scope & Methodology Summary |
TABLE 17 Detailed Sources and Citations |
TABLE 18 North America Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 19 North America Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 20 Europe Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 21 Europe Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 22 Asia-Pacific Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 23 Asia-Pacific Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 24 South America Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 25 South America Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 26 Middle East & Africa Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 27 Middle East & Africa Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 28 United States Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 29 United States Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 30 Canada Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 31 Canada Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 32 Mexico Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 33 Mexico Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 34 Germany Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 35 Germany Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 36 United Kingdom Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 37 United Kingdom Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 38 France Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 39 France Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 40 Italy Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 41 Italy Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 42 Spain Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 43 Spain Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 44 China Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 45 China Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 46 India Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 47 India Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 48 Japan Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 49 Japan Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 50 South Korea Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 51 South Korea Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 52 Brazil Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 53 Brazil Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 54 Saudi Arabia Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 55 Saudi Arabia Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 56 South Africa Influenza Diagnostics Market Size, by Test Type, 2021–2035 (USD Billion) |
TABLE 57 South Africa Influenza Diagnostics Market Size, by End User, 2021–2035 (USD Billion)
13 LIST OF FIGURES |
FIGURE 1 Global Influenza Diagnostics Market Dynamics Overview |
FIGURE 2 Industry Value Chain Analysis – Influenza Diagnostics Market |
FIGURE 3 Porter's Five Forces Analysis – Influenza Diagnostics Market |
FIGURE 4 Global Influenza Diagnostics Market Size Trend & Forecast, 2021–2035 (USD Billion) |
FIGURE 5 Global Influenza Diagnostics Market Share, by Test Type, 2025 |
FIGURE 6 Global Influenza Diagnostics Market Share, by End User, 2025 |
FIGURE 7 Global Influenza Diagnostics Market Share, by Region, 2025 |
FIGURE 8 North America Influenza Diagnostics Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 9 Europe Influenza Diagnostics Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 10 Asia-Pacific Influenza Diagnostics Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 11 South America Influenza Diagnostics Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 12 Middle East & Africa Influenza Diagnostics Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 13 Competitive Landscape Heat Map – Global Influenza Diagnostics Market, 2025 |
FIGURE 14 Market Share Analysis by Company, 2025 (%) |
FIGURE 15 Influenza Diagnostics Market CAGR by Segment, 2026–2035 |
FIGURE 16 Year-over-Year Growth Rate Analysis, 2021–2035

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment (2025)	Fastest Growing Segment (2026–2035)
By Test Type — Traditional	Rapid Influenza Diagnostic Tests, Viral Culture, Other Traditional Tests	Rapid Influenza Diagnostic Tests	Rapid Influenza Diagnostic Tests
By Test Type — Molecular	RT-PCR, LAMP, Other Molecular Tests (incl. CRISPR)	RT-PCR	Other Molecular Tests (incl. CRISPR)
By End User	Hospitals & Clinical Laboratories, Independent Diagnostic Laboratories, Point-of-Care Settings, Other End Users	Hospitals & Clinical Laboratories	Point-of-Care Settings
By Geography	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Test Type

Sub-Segment	Key Trend
Rapid Influenza Diagnostic Tests	Continued high-volume use in POC and pharmacy channels despite sensitivity limitations
Viral Culture	Declining clinical use, retained for WHO reference strain characterization
Other Traditional Tests	Immunofluorescence remains a confirmation tool in select hospital settings.
RT-PCR	Gold-standard molecular platform with an established hospital-installed base
LAMP	Growing adoption in decentralized and resource-limited settings
Other Molecular Tests (incl. CRISPR)	Fastest-growing sub-segment; CRISPR offers molecular accuracy at near-antigen price

The test type dimension reflects the ongoing bifurcation between speed-first antigen tests and accuracy-first molecular platforms. Rapid Influenza Diagnostic Tests retain volume dominance due to low cost and sub-15-minute turnaround, while CRISPR-based assays represent the most disruptive emerging category, projected to grow at a 10.0% CAGR as manufacturing scale matures.

By End User

Sub-Segment	Key Trend
Hospitals and Clinical Laboratories	Standardization on single-vendor molecular platforms via reagent-rental contracts
Independent Diagnostic Laboratories	Insurance-billed reference testing and multi-pathogen panel workflows
Point-of-Care Settings	OTC test adoption, telehealth test-and-treat integration, pharmacy distribution
Other End Users	Research institutions and veterinary laboratories for surveillance applications

End-user segmentation captures the structural shift from centralized to decentralized testing. Hospitals maintain the largest share through established procurement infrastructure, while point-of-care settings grow fastest as consumer self-testing habits forged during COVID-19 extend to seasonal influenza diagnostics.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”